PCSK9 Inhibition: A Revolution in Cholesterol Therapy

San Diego, CA US

Saturday, March 7, 2015 | 5:45 – 8:00 AM PST
Hilton San Diego Bayfront Hotel, Sapphire Ballroom D

This course is a live CME-certified ancillary symposium presented at ENDO 2015, the Endocrine Society's 97th Annual Meeting and Expo, held in San Deigo, California, March 5–8, 2015. ENDO 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2015 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2015 to attend an ENDO 2015 ancillary  symposium.

This activity is supported by an educational grant from sanofi-aventis U.S. 

SYMPOSIUM AGENDA

Welcome and Introduction
Program Director: Sergio Fazio, MD, PhD – Oregon Health and Science University

Current Challenges in Cholesterol Therapy and ASCVD
Sergio Fazio, MD, PhD – Oregon Health and Science University

Uncovering the Biologic and Genetic Aspects of PCSK9 and the LDL Receptor
Speaker TBD

PCSK9 Inhibitors – Mechanism of Action, Safety, and Clinical Efficacy
Kenneth R. Feingold, MD – University of California, San Francisco

Potential Applications of PCSK9 Inhibitors in Clinical Practice
Evan A. Stein, MD,PhD – Metabolic and Atherosclerosis Research Center

Case Presentation/Roundtable Discussion

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals treating lipid disorders.

Learning Objectives

Upon completion of this educational activity, participants will be able to (or better able to):

  • Discuss current challenges in the treatment of patients with hypercholesterolemia
  • Understand genetic factors in hyperlipidemia and FH to assess risk for developing ASCVD in adolescents and adults
  • Describe the biology of PCSK9 in LDL cholesterol metabolism and the mechanism of action of emerging PCSK9 inhibitors
  • Evaluate effectiveness and potential limitations of current and emerging pharmacotherapy options for LDL reduction in patients with hypercholesterolemia and high ASCVD risk

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
03/07/2015
Course expires: 
03/07/2016
Rating: 
0
Hilton San Diego Bayfront
1 Park Boulevard
Sapphire Ballroom D
San Diego, CA 92101
United States

Sergio Fazio, MD, PhD – Program Director
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, Oregon

Kenneth R. Feingold, MD
Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center
San Francisco, California

Evan A. Stein, MD, PhD
Director Emeritus
Metabolic and Atherosclerosis Research Center
Cincinnati, Ohio

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported relevant financial relationships: 
Sergio Fazio, MD, PhD: Advisory Board Member and Ad Hoc Consultant, Merck & Co.; Ad Hoc Consultant, Amarin, Kowa, Lupin, Roche Pharmaceuticals, Sanofi
Kenneth R. Feingold, MD: Principal Investigator and Speaker, Merck & Co.; Speaker, Sanofi
Evan A. Stein, MD, PhD: Ad Hoc Consultant, Amgen, Bristol-Myers Squibb, Genentech, Inc., Sanofi

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Connie B. Newman, MD

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl B. Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Andrea L. Utz, MD, PhD: Investigator, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Larry Fox, MD; Michael S. Irwig, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation

Accreditation Period

Course opens: 
03/07/2015
Course expires: 
03/07/2016